抗血管生成药物联合EGFR-TKI在晚期NSCLC治疗中的应用

)60545X.Р [1 2]Gridelli C,Morgillo F,Favaretto A,et al.Sorafenib binationР[4]Seto T,Kato T,Nishio M,et al.Erlotinib alone or with bevacizumabР with erlotinib or with gemcitabine in elderly patients with advancedР as firstline therapy in patients with advanced nonsquamous nonР nonsmallcell lung cancer:a randomized phase Ⅱ study[J].AnnР smallcell lung cancer harbouring EGFR mutations (JO25567 ):anР Oncol,201 1 , 22 (7 ): 1 5281534. DOI: 1 0.1093 /annonc /Р openlabel,randomised,multicentre,phase 2 study [J ].LancetР mdq630.Р Oncol,201 4,1 5 (1 1 ):1 2361244.DOI:1 0.101 6 /S1 4702045Р (1 4)70381 X.Р (收稿日期:201 60317 修回日期:201 60617)Р[5]Ichihara E,Hotta K,Nogami N,et al.Phase Ⅱ trial of gefitinib inР (本文编辑:张晶晶)Р combination with bevacizumab as firstline therapy for advanced non